|
|
 |
|
Viewing report
|
|
|
|
Special Report - The Autism Spectrum Disorders Market: Substantial Opportunity and Unique Challenges
Decision Resources, Inc., Aug 2009, Pages: 28
An increase in public funding for research and a heightened interest among drug developers suggest that a breakthrough in autism spectrum disorder (ASD) treatment may be imminent. However, drug development has been slow, plagued by a limited understanding of the disease and the difficulties in developing treatments for pediatric populations in general and in ASD in particular. However, substantial opportunity exists for an agent that can safely improve an autistic child’s ability to interact and adapt to his or her surroundings.
Questions Answered in This Report
ASD includes three distinct diagnoses: Asperger’s disorder, classic autism, and pervasive development disorder—not otherwise specified.
- What are the common symptoms in these disorders?
- How do they differ from one another?
- What is known about the cause of the disease?
Public awareness of ASD has increased substantially over the last ten years, and Decision Resources has conducted a comprehensive review of the epidemiology of this indication.
- How many children in the United States are diagnosed with ASD?
- How will this population grow over the next ten years?
- How is ASD diagnosed?
Janssen’s Risperdal is the only agent approved for the treatment of ASD. What are the goals of drug treatment in ASD?
- How effective are current therapies? What is the potential of emerging agents?
One interviewed thought leader treating ASD characterizes current treatments as “throwing a dart at the board.”
- What do thought leaders say about emerging approaches?
- Why does glutamate excitotoxicity particularly intrigue them?
- What treatment challenges and needs do they identify?
Scope
- Overview of ASD: Disease description and symptoms, etiology, diagnosis.
- Epidemiology: Prevalent cases of ASD in the United States, forecasted prevalence to 2018, evaluation of trends in ASD prevalence.
- Primary research: Interviews with thought-leading specialists treating ASD as well as their opinions on current and emerging agents and treatment dynamics.
- Current treatments: Atypical antipsychotics, antidepressants, stimulants, antiepileptics, complementary and alternative medicine (CAM).
- Emerging treatments: Forest Laboratories/Merz’s Namenda (memantine), BioMarin’s Kuvan, Seaside Therapeutics’ STX-209, Curemark’s CM-AT.
- Outlook: 2008 major-market (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) sales, potential of emerging agents.
Customers who bought this item also bought
Autism Spectrum Disorders - High Unmet Needs Create Significant Market Opportunities
Product Profiles: Autism Spectrum Disorders - Underserved Market Eagerly Anticipates Pipeline Trial Data
R&D Trends: Autism Spectrum Disorders
R&D Trends: Autism Spectrum Disorders - Unknown etiology and low industry interest hinders pipeline progression
Case Study: Autism Spectrum Disorders - Public awareness and physician detailing will drive market growth
Current Treatments, Unmet Needs, and Opportunities in Treating Pediatric Crohn’s Disease
Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis?
Epidemiology: Autism Spectrum Disorders
Therapeutic Strategies in Schizophrenia
Will the Approval of New Agents Redefine the Cystic Fibrosis Market?
|
|
|
|
